Update on FDA Priority Review of Dupixent® (dupilumab)

TARRYTOWN, N.Y. and PARIS, May 31, 2024 -- Regeneron Pharmaceuticals, Inc. and Sanofi today announced the U.S. Food and Drug Administration has extended by three months the target action date of...

Related Keywords

Japan , Massachusetts , United States , Paris , France General , France , China , Nathalie Pham , Sandrine Guendoul , Evan Berland , Hannah Kwagh , Timothy Gilbert , Georged Yancopoulos , Regeneron Velocimmune , Arnaud Delepine , Tarik Elgoutni , Vesna Tosic , Corentine Driancourt , Eva Schaefer Jansen , Felix Lauscher , Regeneron Genetics Center , Instagram , Committee For Medicinal Products Human Use , Regeneron Pharmaceuticals Inc , Euronext , Drug Administration , Facebook , Dupilumab Development Program , Nasdaq , Exchange Commission , European Union , European Medicines Agency , Linkedin , Clinical Research Program , Us Department Of Justice , Biologics License Application , Medicinal Products , Human Use , Chief Scientific Officer , Nasal Polyposis , Prescribing Information , Regeneron Genetics , Forward Looking Statements , Regeneron Pharmaceuticals , Product Candidates , Private Securities Litigation Reform Act , Statement Regarding Forward Looking ,